EFFICIENT CARBOPLATIN SINGLE THERAPY IN A MOUSE MODEL OF HUMAN TESTICULAR NONSEMINOMATOUS GERM CELL TUMOR
- 1 January 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 167 (1), 368-374
- https://doi.org/10.1016/s0022-5347(05)65470-5
Abstract
Purpose: Cisplatin based combination therapy has shown excellent clinical results in patients with testicular nonseminomatous germ cell tumor but chemotherapy induced morbidity and reduced patient compliance are limiting factors in this regimen. To decrease cisplatin based combination therapy induced morbidity we examined carboplatin versus etoposide single therapy in an animal model. Materials and Methods: A total of 180 SCID mice bearing testicular nonseminomatous germ cell tumor xenografts received 120 mg./kg. carboplatin as a single cycle, 60 or 30 mg./kg. carboplatin cycled twice, 80, 50 or 30 mg./kg. etoposide cycled twice, or Ringer solution as the control. An additional 20 sham treated and 20 untreated mice also served as controls. Histological and immunocytochemical testing, in vivo microscopy, vascular corrosion casting, serum tumor markers, complete blood count and real-time polymerase chain reaction were used to monitor therapy efficacy. Results: Carboplatin at 60 mg./kg. cycled twice eradicated the tumor and significantly reduced vascular density and vascular endothelial growth factor-A messenger RNA (p <0.05). Elevated tumor markers returned to baseline after carboplatin administration. Therapy was well tolerated, resulting thrombocytopenia disappeared 6 weeks after therapy and the animals were tumor-free 6 months after treatment. Although 120 mg./kg. carboplatin eradicated the tumor, it resulted in extensive mortality and morbidity. Single treatment 30, 50 and 80 mg./kg. etoposide failed. Conclusions: Carboplatin single therapy was highly effective in our nonseminomatous germ cell tumor model and it may be examined in future clinical trials in patients with high risk stage I nonseminomatous germ cell cancer for reducing cisplatin based combination therapy induced morbidity. Vascular density and vascular endothelial growth factor messenger RNA were elevated in our animal model and deserve further study in nonseminomatous germ cell tumor cases as potential risk factors.Keywords
This publication has 12 references indexed in Scilit:
- Preclinical Assessment of Anti-cancer Therapeutic Strategies using in vivo VideomicroscopyCancer and Metastasis Reviews, 1998
- Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.Journal of Clinical Oncology, 1996
- Können Risikofaktoren die Strategien im Stadium I des Nicht-Seminoms bestimmen?Aktuelle Urologie, 1995
- The Management of Patients with Nonseminomatous Germ Cell Tumors of the Testis with Serologic Disease Only After OrchiectomyJournal of Urology, 1994
- Scanning and transmission electron microscopy and high resolution intravital video‐microscopy of capillaries in the mouse exocrine pancreas, with special emphasis on endothelial cellsThe Anatomical Record, 1993
- Pilot Study to Evaluate Impact of a Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer PatientsJournal of Urology, 1992
- Clinical Stage 1 Testicular Cancer: The Role of Modified Retroperitoneal LymphadenectomyJournal of Urology, 1990
- Short‐course Etoposide, Bleomycin and Cisplatin in the Treatment of Metastatic Germ Cell Tumours. Appraisal of its Potential as Adjuvant Chemotherapy for Stage 1 Testis TumoursBritish Journal of Urology, 1988
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- Etoposide (VP-16–213)New England Journal of Medicine, 1985